Since we observed a reduction of Ahnak mRNA and protein in both early and late-stage BC, Ahnak could be a reliable prognostic indicator for DCIS patients to distinguish between indolent and aggressive DCIS, presumably representing aggressive disease. Here, AHNAK is linked to ductal breast carcinoma in situ.